[1]
|
Huber, J., Foidart, J.M., Wuttke, W., et al. (2000) Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. The European Journal of Contraception and Reproductive Health Care, 5, 25-34.
|
[2]
|
Parsey, K.S. and Pong, A. (2000) An open-label, multi-centered study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception, 61, 105-111.
doi:10.1016/S0010-7824(00)00083-4
|
[3]
|
Dinger, J.C., Heinemann, L.A. and Kühl-Habich, D. (2007) The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception, 75, 344-354.
doi:10.1016/j.contraception.2006.12.019
|
[4]
|
Muhn, P., Krattenmacher, R., Beier, S., et al. (1995) Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 51, 99-110.
doi:10.1016/0010-7824(94)00015-O
|
[5]
|
Foidart, J.M., Oelkers, W. and Heithecker, R. (1995) Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity: A major breakthrough in tomorrow’s oral contraception. Gynecol Snapshot, 3, 13-17.
|
[6]
|
Fuhrmann, U., Krattenmacher, R., Slater, E.P. and Fritzemeier, K.-H. (1996) The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception, 54, 243-251.
doi:10.1016/S0010-7824(96)00195-3
|
[7]
|
Oelkers, W., Foidart, J.-M., Dombrovicz, N., et al. (1995) Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the reninaldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. The Journal of Clinical Endocrinology & Metabolism, 80, 1816-1821.
doi:10.1210/jc.80.6.1816
|
[8]
|
Oelkers, W., Helmerhorst, F.M., Wuttke, W., et al. (2000) Effect of an oral contraceptive containing drospirenone on the renin-aldosterone system in healthy female volunteers. Gynecological Endocrinology, 14, 204-213.
doi:10.3109/09513590009167683
|
[9]
|
Endrikat, J., Milchev, N.P., Kapamadzija, A., Georgievska, J., Gerlinger, C., Schmidt, W. and Feroze, S. (2009) Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception, 79, 428-432.
doi:10.1016/j.contraception.2008.12.007
|
[10]
|
Foidart, J.M., Wuttke, W., Bouw, G.M., Gerlinger, C. and Heithecker, R. (2000) A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. The European Journal of Contraception and Reproductive Health Care, 5, 124-134.
doi:10.1080/13625180008500387
|
[11]
|
Moos, R.H. (1968) The development of a menstrual distress questionnaire. Psychosomatic Medicine, 30, 843-867.
|
[12]
|
Moos, R.H. (1991) Menstrual distress questionnaire. Western Psychological Services. 12031 Wilshire Boulevard, Los Angeles.
|
[13]
|
Endrikat, J., Sandri, M., Gerlinger, C., et al. (2007) A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 mcg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. The European Journal of Contraception and Reproductive Health Care, 12, 220-228.
doi:10.1080/13625180701440818
|
[14]
|
Brown, C., Ling, F. and Wan, J. (2002) A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. The Journal of Reproductive Medicine, 47, 14-22.
|
[15]
|
Fruzzetti, F., Lazzarini, V., Ricci, C., et al. (2007) Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception, 76, 190-194. doi:10.1016/j.contraception.2007.05.080
|
[16]
|
Fruzzetti, F., Lello, S., Lazzarini, V., et al. (2007) The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: An observational study. Contraception, 75, 199-203.
doi:10.1016/j.contraception.2006.10.011
|
[17]
|
Apter, D., Borsos, A., Baumgärtner, W., et al. (2003) Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. The European Journal of Contraception and Reproductive Health Care, 8, 37-51.
|
[18]
|
Borges, L.E., Andrade, R.P., Aldrighi, J.M., et al. (2006) Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general wellbeing and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception, 74, 446-450.
doi:10.1016/j.contraception.2005.10.016
|